Structure-based design, synthesis, molecular docking, and biological activities of 2-(3-benzoylphenyl) propanoic acid derivatives as dual mechanism drugs
Open Access
- 1 January 2012
- journal article
- research article
- Published by Medknow in Journal of Pharmacy and Bioallied Sciences
- Vol. 4 (1) , 43-50
Abstract
Purpose: 2-(3-benzoyl phenyl)propanohydroxamic acid (2) and 2-{3-[(hydroxyimino)(phenyl)methyl]phenyl}propanoic acid (3) were synthesized from non-steroidal anti-inflammatory drug, ketoprofen as dual-mechanism drugs. Materials and Methods: Structures of the synthesized compounds were established by IR, 1 H NMR, and mass spectroscopy. Both compounds were screened for their anti-inflammatory activity in rat paw edema model and in vitro antitumor activity against 60 human tumor cell lines. Flexible ligand docking studies were performed with different matrix metalloproteinases and cyclooxygenases to gain an insight into the structural preferences for their inhibition. Results: Compound (2) proved out to be more potent than ketoprofen in rat paw edema model. Both compounds showed moderate anticancer activity ranging from 1% to 23% inhibition of growth in 38 cell lines of 8 tumor subpanels at 10 μM concentration in a single dose experiment. Hydroxamic acid analogue was found to be more potent than ketoximic analogue in terms of its antitumor activity. Conclusion: Analysis of docking results together with experimental findings provide a good explanation for the biological activities associated with synthesized compounds which may be fruitful in designing dual-target-directed drugs that may inhibit cyclooxygenases and MMPs for the treatment of cancer.Keywords
This publication has 24 references indexed in Scilit:
- Matrix Metalloproteinases As Novel Biomarker s and Potential Therapeutic Targets in Human CancerJournal of Clinical Oncology, 2009
- FOXO3a Promotes Tumor Cell Invasion through the Induction of Matrix MetalloproteinasesMolecular and Cellular Biology, 2009
- Dual-Target–Directed Drugs that Block Monoamine Oxidase B and Adenosine A Receptors for Parkinson's DiseaseNeurotherapeutics, 2009
- NSAIDs and Cancer Prevention: Targets Downstream of COX-2Annual Review of Medicine, 2007
- The NCI60 human tumour cell line anticancer drug screenNature Reviews Cancer, 2006
- Tyrosine kinase – Role and significance in CancerInternational Journal of Medical Sciences, 2004
- Design and Therapeutic Application of Matrix Metalloproteinase InhibitorsChemical Reviews, 1999
- Remodeling MMPIsNature Biotechnology, 1995
- The National Cancer Institute: cancer drug discovery and development program.1992
- FEASIBILITY OF DRUG SCREENING WITH PANELS OF HUMAN-TUMOR CELL-LINES USING A MICROCULTURE TETRAZOLIUM ASSAY1988